Genetic and environmental determinants of dimethylarginines and association with cardiovascular disease in patients with Type 2 Diabetes

Diabetes Care

Volumn 37, Issue 3, 2014, Pages 846-854

  Anderssohn, Maike ^a   McLachlan, Stela ^b   Lüneburg, Nicole ^a   Robertson, Christine ^b   Schwedhelm, Edzard ^a   Williamson, Rachel M ^c   Strachan, Mark W J ^c   Ajjan, Ramzi ^d   Grant, Peter J ^d   Böger, Rainer H ^a   Price, Jackie F ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CREATININE; DIMETHYLARGININE; GLUCOSE; N(G),N(G) DIMETHYLARGININE; UNCLASSIFIED DRUG; N,N'-DIMETHYLARGININE; N,N-DIMETHYLARGININE;

ADULT; AGED; AGXT2 GENE; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DDAH1 GENE; DDAH2 GENE; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; FEMALE; FOLLOW UP; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENOTYPING TECHNIQUE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREVALENCE; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; ANALOGS AND DERIVATIVES; BLOOD; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENVIRONMENT; GENETICS; GENOTYPE; INTERMITTENT CLAUDICATION; RISK FACTOR;

AGED; ARGININE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENVIRONMENT; FEMALE; GENOTYPE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84896728508     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0546     Document Type: Article

References (34)

1. Boger RH, Maas R, Schulze F, Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortalitydan update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 2009;60: 481-487
2. Abbasi F, Asagmi T, Cooke JP, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001;88:1201-1203
3. Perticone F, Sciacqua A, Maio R, et al. Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. Int J Cardiol 2010;142:236-241
4. Devangelio E, Santilli F, Formoso G, et al. Soluble RAGE in type 2 diabetes: associationwith oxidative stress. Free Radic Biol Med 2007;43:511-518
5. Can A, Bekpinar S, Gurdol F, Tutuncu Y, Unlucerci Y, Dinccag N. Dimethylarginines in patients with type 2 diabetes mellitus: relation with the glycaemic control. Diabetes Res Clin Pract 2011;94:e61-e64
6. Anderson JL, Carlquist JF, Roberts WL, et al.; Intermountain Heart Collaborative Study Group. Asymmetric dimethylarginine, cortisol/cortisone ratio, and C-peptide: markers for diabetes and cardiovascular risk? Am Heart J 2007;153:67-73
7. Boger RH, Sullivan LM, SchwedhelmE, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009; 119:1592-1600
8. Paiva H, Lehtimaki T, Laakso J, et al. Plasma concentrations of asymmetric-dimethylarginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism 2003;52:303-307
9. Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care 2007;30:1834-1839
10. Cavusoglu E, Ruwende C, Chopra V, et al. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography. Atherosclerosis 2010;210:226-231
11. Ellger B, Richir MC, van Leeuwen PA, et al. Glycemic control modulates arginine and asymmetrical-dimethylarginine levels during critical illness by preserving dimethylarginine-dimethylaminohydrolase activity. Endocrinology 2008;149:3148-3157
12. Eid HM, Lyberg T, Arnesen H, Seljeflot I. Insulin and adiponectin inhibit the TNFalpha-induced ADMA accumulation in human endothelial cells: the role of DDAH. Atherosclerosis 2007;194:e1-e8
13. Abhary S, Burdon KP, Kuot A, et al. Sequence variation in DDAH1 and DDAH2 genes is strongly and additively associated with serum ADMA concentrations in individuals with type 2 diabetes. PLoS One 2010;5:e9462
14. Andreozzi F, Presta I, Mannino GC, et al. A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with insulin sensitivity. PLoS One 2012;7:e36224
15. Lu TM, Chung MY, Lin MW, Hsu CP, Lin SJ. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography. Int J Cardiol 2011 a;153:135-140
16. Schutte AE, Schutte R, Huisman HW, et al. Dimethylarginines: their vascular and metabolic roles in Africans and Caucasians. Eur J Endocrinol 2010;162:525-533
17. Luneburg N, von Holten RA, Topper RF, Schwedhelm E, Maas R, Boger RH. Symmetric dimethylarginine is a marker of detrimental outcome in the acute phase after ischaemic stroke: role of renal function. Clin Sci (Lond) 2012;122:105-111
18. Meinitzer A, Kielstein JT, Pilz S, et al. Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem 2011;57:112-121
19. Ogawa T, Kimoto M, Sasaoka K. Dimethylarginine:pyruvate aminotransferase in rats. Purification, properties, and identity with alanine: glyoxylate aminotransferase 2. J Biol Chem 1990;265:20938-20945
20. Rodionov RN, Murry DJ, Vaulman SF, Stevens JW, Lentz SR. Human alanineglyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production. J Biol Chem 2010;285:5385-5391
21. Price JF, Reynolds RM, Mitchell RJ, et al. The Edinburgh Type 2 Diabetes Study: study protocol. BMC Endocr Disord 2008;8:18
22. Marioni RE, Strachan MWJ, Reynolds RM, et al. Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes 2010;59:710-713
23. Williamson RM, Price JF, Glancy S, et al.; ET2DS Investigators. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 2011;34: 1139-1144
24. Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer U, Boger RH. Highthroughput liquid chromatographictandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007;851:211-219
25. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265
26. Krzyzanowska K, Mittermayer F, Krugluger W, et al. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes. Atherosclerosis 2006;189:236-240
27. Krzyzanowska K, Mittermayer F, Shnawa N, et al. Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with Type 2 diabetes and albuminuria. Diabet Med 2007;24:81-86
28. Boger RH, Endres HG, Schwedhelm E, et al. Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease. J Intern Med 2011;269: 349-361
29. Schepers E, Glorieux G, Dhondt A, Leybaert L, Vanholder R. Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrol Dial Transplant 2009;24:1429-1435
30. Schepers E, Barreto DV, Liabeuf S, et al.; European Uremic Toxin Work Group (EUTox). Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. Clin J Am Soc Nephrol 2011;6: 2374-2383
31. Ray A, Huisman MV, Tamsma JT, et al.; Research and Writing-Group. The role of inflammation on atherosclerosis, intermediate and clinical cardiovascular endpoints in type 2 diabetes mellitus. Eur J Intern Med 2009;20:253-260
32. Leiper JM, Santa Maria J, Chubb A, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999;343:209-214
33. Luneburg N, Lieb W, Schwedhelm E, et al. Genome-Wide Association Study of Dimethylarginines Reveals Novel Metabolic Pathway for SDMA. Circulation 2011;124: A12560
34. Schwedhelm E, Xanthakis V, Maas R, et al. Plasma symmetric dimethylarginine reference limits from the Framingham offspring cohort. Clin Chem Lab Med 2011; 49:1907-1910